Monopar Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 2.43 million compared to USD 2.46 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.19 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.705 USD | +15.37% | +13.71% | +107.23% |
May. 24 | Monopar Therapeutics Names Karthik Radhakrishnan as CFO | MT |
May. 24 | Monopar Therapeutics Inc. Announces CFO Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.23% | 10.67M | |
+46.92% | 54.63B | |
-6.68% | 39.92B | |
+37.07% | 38.82B | |
+13.98% | 26.86B | |
-11.17% | 26.22B | |
-21.80% | 18.78B | |
+26.19% | 12.21B | |
+0.72% | 12.16B | |
+26.41% | 11.94B |
- Stock Market
- Equities
- MNPR Stock
- News Monopar Therapeutics Inc.
- Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023